Trading below net cash holdings ahead of that deal, the business faced a challenging outlook. This made it so that I erred on ...

BROOKFIELD, Wis.--(BUSINESS WIRE)--Fiserv, Inc. (NYSE: FI), a leading global provider of payments and financial services technology, and Akoya, an API-only network for the consumer-permissioned ...

After biotech firm Akoya Biosciences previously announced it would be acquired by Billerica-based research corporation Quanterix, the Marlborough-based company is now considering an unsolicited, ...

BILLERICA, Mass. & MARLBOROUGH, Mass., April 29, 2025--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and ...

There is a great battle being waged on your behalf and chances are you don’t even know it. Every day millions of people transact online, in stores, and in mobile apps. All that detail of who, how much ...

Mere weeks after making an unsolicited bid to buy Marlborough-based biotech firm Akoya Biosciences, the anonymous party has withdrawn its offer. The unsolicited offer came May 21 after Akoya had ...

Fiserv Inc. is working with data aggregator Akoya LLC to enable consumers to share their financial data with fintech and third-parties with which they do business in a way that doesn’t expose a ...

BOSTON--(BUSINESS WIRE)--Akoya, a 100% API-connected data access network, announced today an agreement with leading data access platform Envestnet | Yodlee, to help consumers more efficiently manage ...

eMoney Advisor is joining the Akoya Data Access Network as the first data aggregator on the platform, according to an announcement by eMoney. Founded in 2018, the network’s investors include Fidelity ...

MARLBOROUGH, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the fourth quarter and ...

I will provide readers the basics of what a spatial biotech offers. A key catalyst should drive the future of this bioscience company. I will share the caveats needed to understand the issue that ...